Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AnaptysBio, Inc. ANAB
$19.05
-$1.57 (-8.26%)
На 18:00, 12 мая 2023
+67.98%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
561060732.00000000
-
week52high
32.44
-
week52low
18.20
-
Revenue
10287000
-
P/E TTM
-4
-
Beta
-0.15397900
-
EPS
-4.64000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | 01 сент 2022 г. | |
| Guggenheim | Neutral | Buy | 22 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 08 мар 2022 г. |
| HC Wainwright & Co. | Buy | 22 июн 2021 г. | |
| UBS | Neutral | 21 мая 2021 г. | |
| Truist Securities | Hold | Buy | 13 сент 2022 г. |
| Guggenheim | Buy | Neutral | 01 ноя 2022 г. |
| JP Morgan | Underweight | Underweight | 18 ноя 2022 г. |
| Raymond James | Outperform | Outperform | 09 ноя 2022 г. |
| Raymond James | Market Perform | Outperform | 06 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LOUMEAU ERIC J | A | 60530 | 60530 | 06 янв 2023 г. |
| Ware J. Anthony | A | 3900 | 3900 | 06 янв 2023 г. |
| Ware J. Anthony | A | 10600 | 10600 | 06 янв 2023 г. |
| Schmid John P. | A | 3900 | 3900 | 06 янв 2023 г. |
| Schmid John P. | A | 10600 | 10600 | 06 янв 2023 г. |
| Topper James N | A | 3900 | 3900 | 06 янв 2023 г. |
| Topper James N | A | 10600 | 10600 | 06 янв 2023 г. |
| Marquet Magda | A | 3900 | 3900 | 06 янв 2023 г. |
| Marquet Magda | A | 10600 | 10600 | 06 янв 2023 г. |
| MULROY DENNIS | A | 20980 | 20980 | 06 янв 2023 г. |
Новостная лента
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $1.31 per share a year ago.
AnaptysBio: Upside Could Be Lying Ahead Very Nicely
Seeking Alpha
30 мар 2023 г. в 23:44
US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and take advantage of attractive levels. AnaptysBio, Inc. appears to be one of the US-listed biotech stocks worth investing in due to its low stock price combined with some interesting positive catalysts in its treatment pipeline.
GSK's Jemperli Effective Against First-Line Endometrial Cancer
Zacks Investment Research
28 мар 2023 г. в 16:45
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
01 мар 2023 г. в 18:48
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio to Participate in Upcoming November Investor Conferences
GlobeNewsWire
09 ноя 2022 г. в 14:10
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.